Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Dependency ratio

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    50 result(s) found for: Dependency ratio. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2009-011824-79 Sponsor Protocol Number: 91686125 Start Date*: 2009-11-03
    Sponsor Name:Academic Medical Center
    Full Title: Effects of fluoxetine on the outgrowth of the serotonergic system
    Medical condition: We investigate whether the effects fluoxetine (Prozac®) on the outgrowth of the serotonergic system are dependent on age. In a 16 week multicenter randomized, double-blind, placebo controlled trial...
    Disease: Version SOC Term Classification Code Term Level
    15.0 10022891 - Investigations 10056941 MRI brain LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-011251-48 Sponsor Protocol Number: CNTO888PCR2001 Start Date*: 2009-08-28
    Sponsor Name:Janssen Biologics B.V.
    Full Title: An Open-label, Multicenter, Phase 2 Study of Single-agent CNTO 888 (an anti-CCL2 Monoclonal Antibody) for the Treatment of Subjects with Metastatic Castrate-Resistant Prostate Cancer
    Medical condition: Metastatic Castrate-Resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2004-002170-34 Sponsor Protocol Number: 2004-002170-34 Start Date*: 2006-03-29
    Sponsor Name:Cambridge University Hospital (Addenbrookes Hospital)
    Full Title: "Ensayo clínico controlado randomizado sobre el tratamiento precoz con insulina en recién nacidos de muy bajo peso"
    Medical condition: Very low birth weight infants requiring intensive care have relative insulin deficiency often leading to hyperglycaemia during the first week of life. There is increasing evidence that the early po...
    Disease:
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2016-001779-54 Sponsor Protocol Number: GEICAM/2015-04 Start Date*: 2017-01-05
    Sponsor Name:GEICAM (Fundación Grupo Español de Investigación en Cáncer de Mama)
    Full Title: A multicenter phase II trial to evaluate the efficacy and safety of pembrolizumab and gemcitabine in patients with HER2-negative Advanced Breast Cancer (ABC). “PANGEA-Breast”
    Medical condition: Patients with HER2-negative advanced breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10072737 Advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2017-001025-41 Sponsor Protocol Number: NL61906.018.17 Start Date*: 2018-03-08
    Sponsor Name:Academic Medical Center
    Full Title: Prevention of relapse with Levamisole as adjuvant therapy to corticosteroids in children with first episode of idiopathic nephrotic syndrome
    Medical condition: steroid sensitive idiopathic nephrotic syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.1 10038359 - Renal and urinary disorders 10029164 Nephrotic syndrome PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-002366-13 Sponsor Protocol Number: IB2020-02 Start Date*: 2021-12-20
    Sponsor Name:Institut Bergonié
    Full Title: Combination of pembrolizumab and cabozantinib in patients with advanced sarcomas
    Medical condition: Advanced /metastatic sarcomas: undifferentiated pleomorphic sarcoma, osteosarcoma and Ewing sarcoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10039494 Sarcoma NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-002515-34 Sponsor Protocol Number: CMG012022 Start Date*: 2023-03-28
    Sponsor Name:Czech Myeloma Group
    Full Title: Phase 2 study of belantamab mafodotin in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma
    Medical condition: The study will enroll adult participants with RRMM who have been previously treated with at least 1 prior line of therapy, and who have documented disease progression during, or after, their most r...
    Disease: Version SOC Term Classification Code Term Level
    25.0 100000004864 10086466 Relapsed/refractory multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-004456-30 Sponsor Protocol Number: B9991030 Start Date*: 2018-09-13
    Sponsor Name:Pfizer Inc.
    Full Title: A RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AVELUMAB IN COMBINATION WITH CHEMOTHERAPY FOLLOWED BY MAINTENANCE THERAPY OF AVELUMAB IN COMBINATION WITH...
    Medical condition: PREVIOUSLY UNTREATED ADVANCED OVARIAN CANCER
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10033130 Ovarian cancer NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SK (Prematurely Ended) CZ (Prematurely Ended) HU (Completed) BE (Completed) GB (GB - no longer in EU/EEA) EE (Completed) HR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-004252-38 Sponsor Protocol Number: 207495 Start Date*: 2020-04-14
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide plus Low-dose Dexamethasone (pom/dex) in Participants wit...
    Medical condition: Relapsed/Refractory Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) NL (Trial now transitioned) DE (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) BE (Trial now transitioned) HU (Trial now transitioned) GR (Trial now transitioned) PL (Trial now transitioned) BG (Trial now transitioned) IT (Trial now transitioned)
    Trial results: View results
    EudraCT Number: 2016-002267-33 Sponsor Protocol Number: OCTO-089 Start Date*: 2017-06-13
    Sponsor Name:University of Oxford
    Full Title: A parallel group phase I/II marker lesion study to assess the safety, tolerability and efficacy of intravenous or intravesical pembrolizumab in intermediate risk recurrent non-muscle invasive bladd...
    Medical condition: Intermediate risk recurrent non-muscle invasive bladder cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005056 Bladder neoplasm PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-001327-39 Sponsor Protocol Number: C/37/2017 Start Date*: 2018-11-05
    Sponsor Name:Imperial College London
    Full Title: A Phase II, Two-Stage, Trial of Pembrolizumab in Cancer of unknown primary - CUPem
    Medical condition: CUP, Cancer of Unknown Primary
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2018-002882-20 Sponsor Protocol Number: Start Date*: 2019-04-17
    Sponsor Name:Imperial College London
    Full Title: A multicentre randomised controlled trial to assess the safety and efficacy of adding rituximab to standard of care in treating acute antibody-mediated rejection in kidney transplantation (Transpla...
    Medical condition: Renal Transplant antibody-mediated rejection
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10023439 Kidney transplant rejection PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2020-001696-32 Sponsor Protocol Number: GC2004 Start Date*: 2020-05-08
    Sponsor Name:Instituto Grifols, S.A
    Full Title: A Multicenter, Randomized, Open-label Parallel Group Pilot Study to Evaluate Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) plus Standard Medical Treatment (SMT) versus SMT alo...
    Medical condition: Patients with Mild to Moderate Coronavirus Disease (COVID-19)
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    23.0 10021881 - Infections and infestations 10053983 Corona virus infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2016-001263-37 Sponsor Protocol Number: AGO/2016/003 Start Date*: 2016-06-23
    Sponsor Name:UZ Gent
    Full Title: Phase I trial of stereotactic body radiotherapy with concurrent pembrolizumab in metastatic urothelial cancer.
    Medical condition: Metastatic urothelial cancer
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2017-000689-30 Sponsor Protocol Number: Pem-NSCLC Start Date*: 2018-08-02
    Sponsor Name:Med. Univ. Wien, Klinik f. Innere Med. I, Onkologie
    Full Title: Expression/DNA methylation of cancer testis antigens may predict response to pembrolizumab in pretreated NSCLC patients
    Medical condition: untreated patients with adenocarcinoma of the lung of advanced stage
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2020-001795-15 Sponsor Protocol Number: COMBAT-19 Start Date*: 2020-05-07
    Sponsor Name:OSPEDALE SAN RAFFAELE
    Full Title: A randomized, double blind, placebo-COntrolled trial of MavrilimumaB for Acute respiratory failure due To COVID-19 pneumonia with hyperinflammation: the COMBAT-19 trial
    Medical condition: Respiratory failure during COVID-19 pneumonia and hyperinflammation
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-001576-11 Sponsor Protocol Number: 4010-03-001 Start Date*: 2019-09-10
    Sponsor Name:TESARO, Inc.
    Full Title: A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) plus Carboplatin-paclitaxel versus Placebo Plus Carboplatin-paclitaxel in Patients with Recurrent or Primary Advanced...
    Medical condition: Recurrent or primary advanced (Stage III or IV) endometrial cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014740 Endometrial cancer stage III PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014741 Endometrial cancer stage IV PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Trial now transitioned) DK (Trial now transitioned) NO (Trial now transitioned) PL (Trial now transitioned) FI (Trial now transitioned) DE (Trial now transitioned) BE (Trial now transitioned) NL (Trial now transitioned) GB (GB - no longer in EU/EEA) GR (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-000550-60 Sponsor Protocol Number: V7/22032018 Start Date*: 2014-01-17
    Sponsor Name:Medizinische Universität Wien, Klinische Abteilung für Nephrologie und Dialyse, Universitätsklinik für Innere Medizin 3
    Full Title: Pulsed oral sirolimus in autosomal dominant polycystic kidney disease
    Medical condition: Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disorder characterized by the development and uncontrolled proliferation of innumerable epithelial-lined cysts that stem from renal...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10036046 Polycystic kidney, autosomal dominant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-005458-27 Sponsor Protocol Number: MK-4830-002 Start Date*: 2022-04-28
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Randomized, Phase 2 Study of Pembrolizumab And Chemotherapy With or Without MK-4830 as Neoadjuvant Treatment for High-Grade Serous Ovarian Cancer
    Medical condition: First-line treatment of advanced High Grade Serous Ovarian Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Trial now transitioned) IT (Trial now transitioned) PL (Trial now transitioned) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-000916-14 Sponsor Protocol Number: E7080-G000-307 Start Date*: 2017-07-19
    Sponsor Name:Eisai Ltd.
    Full Title: A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment ...
    Medical condition: Advanced Renal Cell Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050513 Metastatic renal cell carcinoma PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) CZ (Completed) IE (Completed) AT (Completed) BE (Completed) ES (Completed) PL (Completed) GR (Completed) NL (Completed) IT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 04 11:47:56 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA